brent

Inhaled Insulin: One Giant Leap for MannKind

Vyceroy, if you like Exubera, you'll love Technosphere. And LJ, in fairness, you don't know what you're talking about. They're a research team surviving on stock sales? They're surviving because the founder and CEO, Al Mann, has pumped more than a billion dollars of his own money into the company to fund r&d because he believes this product will be the biggest drug ever. The diabetic market is HUGE (pun intended). Maybe you've never heard of Al Mann and wonder how he comes to have a spare billion to invest in this company. Well, he took two other biotechs from startup to multi-billion dollar companies, helped countless people, contributed to humanity, and made billions in the process. A repetition confusing the investing public? Idiotic.
The website link is to a CNBC interview with the Mann himself. In it, the self-made pharma-billionaire says Technosphere is technologically superior to the failed inhalables in the way it delivers insulin and offers significant clinical advantages to current insulin therapies, allowing the patient to manage his or her blood sugar levels more effectively without having to stick needles in the skin. As he says, it changes the whole paradigm of therapy. Exubera's failure and the other companies withdrawals simply eliminates potential competition. When Al Mann again proves he's got the Midas Touch, like in every other venture he's ever attempted, people are going to wish they'd bought when it was this low.
Full disclosure, I'm invested.